Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co in Multiple Transactions

Lilly Endowment Inc. sold 20,383 shares of Eli Lilly & Co. common stock in multiple transactions on June 5, 2024, at weighted average prices of $836.14 and $837.653.

Summary

• Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co., sold a total of 20,383 shares of common stock on June 5, 2024.
• The sales were executed in multiple transactions at weighted average prices of $836.14 for 17,983 shares and $837.653 for 2,400 shares.
• Following these transactions, Lilly Endowment Inc. beneficially owns 98,188,427 shares of Eli Lilly & Co. common stock.
• The sales were conducted under a pre-arranged plan, as indicated by the check box for Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: The document is a neutral report of a stock sale, with no indication of positive or negative sentiment.

Industry Context

This is a routine filing for a significant shareholder selling shares, and it does not indicate any specific trend in the pharmaceutical industry.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and large shareholders.
• The sale of shares by Lilly Endowment Inc. is not unusual for large institutional investors managing their portfolios.
• Comparable transactions are regularly seen across the market for companies with significant institutional ownership.

Stakeholder Impact

• The sale of shares may have a minor impact on the stock price, but it is unlikely to significantly affect other stakeholders.

Key Dates

Keywords

Lilly Endowment Inc., Eli Lilly & Co, share sale, stock transaction, beneficial ownership, Form 4, Rule 10b5-1